{"id":"losmapimod-tablets","safety":{"commonSideEffects":[{"rate":"10%","effect":"Headache"},{"rate":"8%","effect":"Dizziness"},{"rate":"5%","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Losmapimod is a selective inhibitor of Rho kinase, which plays a role in the regulation of smooth muscle contraction and inflammation.","oneSentence":"Rho kinase inhibitor","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:37:59.847Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"}]},"trialDetails":[{"nctId":"NCT05397470","phase":"PHASE3","title":"Efficacy and Safety of Losmapimod in Treating Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) (REACH)","status":"TERMINATED","sponsor":"Fulcrum Therapeutics","startDate":"2022-06-16","conditions":"Facioscapulohumeral Muscular Dystrophy (FSHD)","enrollment":260},{"nctId":"NCT04003974","phase":"PHASE2","title":"Efficacy and Safety of Losmapimod in Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD)","status":"COMPLETED","sponsor":"Fulcrum Therapeutics","startDate":"2019-08-09","conditions":"Facioscapulohumeral Muscular Dystrophy (FSHD)","enrollment":80},{"nctId":"NCT04511819","phase":"PHASE3","title":"Losmapimod Safety and Efficacy in COVID-19","status":"TERMINATED","sponsor":"Fulcrum Therapeutics","startDate":"2020-08-28","conditions":"COVID-19","enrollment":52},{"nctId":"NCT05002231","phase":"PHASE1","title":"Relative Bioavailability and Food Effect Study of Losmapimod 15 mg Tablets","status":"COMPLETED","sponsor":"Fulcrum Therapeutics","startDate":"2021-08-19","conditions":"Healthy Adult Subjects","enrollment":18},{"nctId":"NCT00633022","phase":"PHASE2","title":"A Study to Evaluate the Effects of 3 Months Dosing With GW856553, as Assessed FDG-PET/CT Imaging","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-06-02","conditions":"Atherosclerosis","enrollment":99},{"nctId":"NCT02299375","phase":"PHASE2","title":"Safety and Efficacy Study of Losmapimod (GW856553) in Frequently Exacerbating Participants With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-12-09","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":184},{"nctId":"NCT01218126","phase":"PHASE2","title":"Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-centre, Dose Ranging Study to Evaluate the Efficacy and Safety of Losmapimod Tablets Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease (COPD).","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-11-04","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":604},{"nctId":"NCT01648192","phase":"PHASE1","title":"Phase I Study of GW856553 (Losmapimod)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-07-24","conditions":"Acute Coronary Syndrome","enrollment":20},{"nctId":"NCT01039961","phase":"PHASE1","title":"PK Study of IV Formulation of GW856553","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-02-02","conditions":"Cardiovascular Disease","enrollment":16},{"nctId":"NCT02000440","phase":"PHASE2","title":"A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-07-01","conditions":"Glomerulosclerosis, Focal Segmental","enrollment":17},{"nctId":"NCT01756495","phase":"PHASE1","title":"A Study to Evaluate the Effect of Losmapimod on Cardiac Conduction as Compared to Placebo and Moxifloxacin","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-01-10","conditions":"Acute Coronary Syndrome","enrollment":56},{"nctId":"NCT02145468","phase":"PHASE3","title":"A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-06-03","conditions":"Acute Coronary Syndrome","enrollment":3503},{"nctId":"NCT01541852","phase":"PHASE2","title":"Losmapimod in Chronic Obstructive Pulmonary Disease Patients Stratified by Fibrinogen.","status":"COMPLETED","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2012-06","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":72}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Losmapimod tablets","genericName":"Losmapimod tablets","companyName":"GlaxoSmithKline","companyId":"glaxosmithkline","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rho kinase inhibitor Used for Hypertension.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}